Remove Ablation Remove Circulation Remove Pericarditis
article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.

article thumbnail

Colchicine to Prevent Atrial Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-Controlled Trial

Circulation: Arrhythmia and Electrophysiology

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Inflammation may promote atrial fibrillation (AF) recurrence after catheter ablation. The first dose of the study drug was administered within 4 hours before ablation. 1.61];P=0.92) or at 3 months following ablation (14% versus 15%; HR, 0.95 [95% CI, 0.45–2.02];P=0.89).

article thumbnail

Pulsed Field Ablation Using Focal Contact Force–Sensing Catheters for Treatment of Atrial Fibrillation: 1-Year Outcomes of the ECLIPSE AF Study

Circulation: Arrhythmia and Electrophysiology

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. There were no incidences of adverse event fistula, diaphragmatic paralysis, MI, pericarditis, thromboembolism, PV stenosis, transient ischemic attack, or death.